PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.

Importantly, the triple combination with any of the three tested CBL-Bi doses significantly delayed tumor growth at all concentrations, associated to a very highly significant increase in survival (Fig. 6E–G ).

also in 132,142 other papers